MediWound Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound or view top-rated stocks.

Wall Street analysts have given MediWound a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MediWound wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

MediWound saw a drop in short interest in March. As of March 31st, there was short interest totaling 42,300 shares, a drop of 47.6% from the March 15th total of 80,800 shares. Based on an average daily trading volume, of 163,100 shares, the short-interest ratio is currently 0.3 days. Currently, 0.2% of the shares of the company are sold short.
View MediWound's Short Interest.

MediWound is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for MediWound.

MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.05. The biopharmaceutical company earned $6.67 million during the quarter, compared to analysts' expectations of $5.59 million. MediWound had a negative net margin of 53.12% and a negative trailing twelve-month return on equity of 94.63%.
View MediWound's earnings history.

MediWound's stock was trading at $2.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have increased by 118.2% and is now trading at $5.04.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued 12 month price objectives for MediWound's stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate MediWound's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 48.8% from the stock's current price.
View analysts' price targets for MediWound or view top-rated stocks among Wall Street analysts.

Some companies that are related to MediWound include ChromaDex (CDXC), Canopy Rivers (RIV), Charlie's (CHUC), Natural Alternatives International (NAII), Nutra Pharma (NPHC), Happiness Biotech Group (HAPP), Mannatech (MTEX), Glucose Health (GLUC), FitLife Brands (FTLF), True Drinks (TRUU), FSD Pharma (HUGE), Tauriga Sciences (TAUG), Heyu Biological Technology (HYBT), Cyanotech (CYAN) and GLG Life Tech (GLGLF).
View all of MDWD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), The Blackstone Group (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDWD stock can currently be purchased for approximately $5.04.

MediWound has a market capitalization of $137.27 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis.

MediWound employs 75 workers across the globe.

The official website for MediWound is www.mediwound.com.

MediWound is headquartered at 42 HAYARKON STREET, YAVNE L3, 8122745.

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]